{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089298","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.205907+00:00","generated_at":"2026-06-11T21:26:33.260668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cyclacel Q2 2023 net loss $5.4M; cash $10.2M, runway to end of 2023","bullets":["Net loss of $5.4M for Q2 2023 vs $4.6M Q2 2022; cash $10.2M at June 30, 2023 (down from $18.3M Dec 2022).","R&D expenses $4.7M in Q2 2023 vs $4.2M Q2 2022; fadraciclib $3.0M, plogosertib $1.4M.","Cash expected to fund programs through end of 2023; discretionary cuts could extend to Q2 2024.","Phase 1/2 data for fadraciclib and plogosertib expected in 2023; tumor shrinkage observed in several cancer types."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089298","json":"https://secwatch.observer/filing/0001104659-23-089298.json","markdown":"https://secwatch.observer/filing/0001104659-23-089298.md","text":"https://secwatch.observer/filing/0001104659-23-089298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/0001104659-23-089298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/tm2323211d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:26:33.260668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d19e61aadfb15984aade270c81af63155c311b8","claim":"Bio Green Med Solution, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $5.4 million.","evidence_excerpt":"Net loss for the three months ended June 30, 2023, was $5.4 million, compared to $4.6 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/0001104659-23-089298-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the three months ended June 30, 2023, was $5.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"725357869c69610a37d1f304da166982ae5a1786","claim":"Bio Green Med Solution, Inc. reported financial results for six months ended June 30, 2023.","evidence_excerpt":"Net loss for the three months ended June 30, 2023, was $5.4 million, compared to $4.6 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/0001104659-23-089298-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}